| Literature DB >> 27822348 |
Aas Van den Bosch1, Hjmm Mertens2.
Abstract
AIM OF THE STUDY: Even in oncology, minimal invasive surgery is introduced. We describe the introduction of this new surgical technique in a teaching hospital. The objective was to compare factors that have influenced the choice between laparoscopic versus open surgery in patients with endometrial cancer.Entities:
Keywords: Endometrial cancer; implementation; laparoscopy; minimal invasive treatment; open surgery; technique
Year: 2016 PMID: 27822348 PMCID: PMC5096424
Source DB: PubMed Journal: Facts Views Vis Obgyn ISSN: 2032-0418
Fig. 1— Patient selection
This figure shows all patients that were operated for endometrial cancer in this study. In the bottom line, the follow up of these patients is added (AUE = abdominal uterus extirpation, BSO = bilateral salpingo-oophorectomy, LAVH = laparoscopic assisted vaginal hysterectomy, NED = no evidence of disease; AWD = alive with disease; DOC = death other cause, DOD = death on disease.
Fig. 2— 2013-2014: number of laparoscopies and laparotomies each year (Group I: Laparoscopy; Group II: Conversion after laparoscopy; Group IIIa:Laparotomy in low grade endometrial cancer; Group IIIb: Laparotomy in high grade endometrial cancer).
— Peri- and postoperative baseline characteristics in patients that were operated because of endometrial cancer in this study (laparoscopy = group I; conversion = group II; laparotomy invalid = group IIIa; laparotomy valid = group IIIB).
|
Laparoscopy |
Conversion |
Laparotomy | p-value | |||
| Laparotomy invalid (n = 24) | Laparotomy valid (n = 47) | |||||
| Postoperative type of tumour | 0.55 | |||||
| Endometrioid Adenocarcinoma | 17 (94.4%) | 5 (100%) | 23 (95.8%) | 34 (72.3%) | ||
| Serous Carcinoma | 0 | 0 | 0 | 6 (12.8%) | ||
| Clear Cell Carcinoma | 0 | 0 | 1 (4.2%) | 6 (12.7%) | ||
| No malignancy | 1 (5.6%) | 1 (2.1%) | ||||
| Postoperative grade of tumour | 0.01 | |||||
| Good | 10 (55.6%) | 4 (80.0%) | 12 (50.0%) | 7 (12.8%) | ||
| Moderate | 7 (38.9%) | 1 (20.0%) | 7 (29.2%) | 23 (48.9%) | ||
| Poor | 0 | 0 | 5 (20.8%) | 16 (3.0%) | ||
| No malignancy | 1 (5.6%) | 1 (4.3%) | ||||
| Mean uterus weight in grams (95%-CI) | 161.0 (99.9- 221.5) | 338.9 (10.2- 402.7) | 211.5 (113.0- 323.9) | 196.9 (151.1- 260.7) | < 0.30 | |
| Uterus weight | 0.92 | |||||
| < 300 grams | 13 (72.2%) | 3 (60.0%) | 20 (83.3%) | 40 (85.1%) | ||
| > 300 grams | 2 (11.1%) | 1 (20.0%) | 3 (12.5%) | 6 (12.8%) | ||
| Unknown | 3 (16.7%) | 1 (20.0%) | 1 (4.2%) | 1 (2.1%) | ||
| FIGO stage | < 0.03 | |||||
| IA | 13 (72.2%) | 3 (60.0%) | 14 (58.3%) | 25 (53.2%) | ||
| IB | 3 (16.7%) | 1 (20.0%) | 8 (33.3%) | 16 (34.0%) | ||
| II | 0 | 1 (20.0%) | 1 (4.2%) | 2 (4.3%) | ||
| IIIA | 2 (11.1%) | 0 | 1 (4.2%) | 2 (4.3%) | ||
| IIIC | 0 | 0 | 0 | 2 (4.3%) | ||
| Blood loss, mean in ml (95%-CI) | 91.1 (34.3- 104.0) | 359.8 (385.3- 885.3) | 242.5 (189.8- 284.8) | 264.2 (236.9- 298.0) | < 0.01 | |
| Mean length of hospitalization, days (95%-CI) | 3.1 (2.1-3.4) | 4.6 | 4.4 (3.7-5.0) | 4.9 (4.2-5.3) | < 0.01 | |
| Complications | 0 | 2 (40.0%) | 1 (4.1%) | 3 (6.4%) | 0.78 | |
| Relapse | 0 | 0 | 2 (8.3%) | 1 (2.1%) | 0.48 | |
| Follow up | 0.79 | |||||
| NED | 15 (83.3%) | 5 (100%) | 21 (87.5%) | 43 (91.5%) | ||
| AWD | 0 | 0 | 2 (8.3%) | 1 (2.1%) | ||
| DOD | 1 (5.6%) | 0 | 1 (4.2%) | 1 (2.1%) | ||
| DOC | 2 (11.1%) | 0 | 0 | 2 (4.3%) | ||
Fig. 3— Clinical relevant post-operative baseline characteristics. The left part of this figure shows different surgical procedures (laparoscopy is group I; conversion is group II, laparotomy invalid is group IIIa and laparotomy valid is group IIIB) in respect to postoperative baseline characteristics in patients that were operated because of endometrial cancer in this study (length of hospital stay, blood loss, overall complications, follow up). The right part shows these different surgical procedures in respect to FIGO stages of endometrial cancer.
— Multivariate logistic regression: odds of indications for planning the right surgery based on the protocol or not.
| OR | 95%-CI | p-value | |
| BMI (> 25 kg/m2) | 1.150 | 0.257-5.144 | 0.855 |
| Menopausal status | 0.476 | 0.071-3.184 | 0.444 |
| Cardiac history | 1.668 | 0.488-5.697 | 0.414 |
| Pulmonal history | 4.477 | 0.476-42.102 | 0.190 |
| Diabetes Mellitus | 0.369 | 0.053-2.541 | 0.311 |
| Coagulation disorder | 3.520 | 0.329-37.647 | 0.298 |
| Previous abdominal surgery | 1.390 | 0.432-4.471 | 0.581 |
| Serum level CA-125 (> 21 U/ml) | 0.155 | 0.015-1.587 | 0.116 |
— Pre-operative baseline characteristics in patients that were operated because of endometrial cancer in this study (laparoscopy = group I; conversion = group II; laparotomy invalid = group IIIa; laparotomy valid = group IIIB).
|
Laparoscopy |
Conversion |
Laparotomy | p-value | |||
| Laparotomy invalid (n = 24) | Laparotomy valid (n = 47) | |||||
| Mean age during diagnosis, years (95%-CI) | 64.3 (54.3-74.2) | 61.5 (55.2-67.9) | 64.7 (60.3-69.2) | 66.3 (63.4-69.4) | 0.41 | |
| Mean BMI, kg/m2 (95%-CI) | 31.9 (27.6-36.2) | 37.6 (29.3-45.8) | 28.4 (26.4-30.3) | 28.4 (26.5-30.3) | 0.12 | |
| Postmenopausal | 14 (77.8%) | 5 (100%) | 21 (87.5%) | 42 (89.4%) | 0.91 | |
| Cardiac history | 9 (50.0%) | 1 (20.0%) | 9 (37.5%) | 23 (48.9%) | 0.36 | |
| Pulmonal history | 2 (11.1%) | 0 | 3 (12.5%) | 1 (2.1%) | 0.34 | |
| Diabetes Mellitus | 0 | 2 (40.0%) | 3 (12.5%) | 11 (23.4%) | 0.30 | |
| Coagulation disorder | 0 | 0 | 2 (8.3%) | 2 (4.3%) | 0.68 | |
| Previous abdominal surgery | 7 (38.9%) | 1 (20.0%) | 8 (33.3%) | 21 (44.7%) | 0.40 | |
| Mean number of previous abdominal surgeries (95%-CI) | 0.7 (0.0-1.4) | 1.7 (0.6-2.8) | 1.4 (1.0-1.8) | 0.14 | ||
| Preoperative type of tumour | < 0.01 | |||||
| Endometrioid Adenocarcinoma | 16 (88.9%) | 4 (80.0%) | 24 (100%) | 34 (72.3%) | ||
| Serous Carcinoma | 0 | 0 | 0 | 11 (23.1%) | ||
| Unknown | 2 (11.1%) | 1 (20.0%) | 0 | 2 (4.3%) | ||
| Preoperative grade of tumour | < 0.01 | |||||
| Good | 10 (55.6%) | 3 (60.0%) | 24 (100%) | 0 | ||
| Moderate | 6 (33.3%) | 1 (20.0%) | 0 | 26 (55.3%) | ||
| Poor | 0 | 0 | 0 | 17 (36.2%) | ||
| Unknown | 2 (11.1%) | 1 (20.0%) | 4 (8.5%) | |||
| Preoperative CA-125 | 0.58 | |||||
| < 21U/ml | 11 (61.1%) | 5 (100%) | 20 (83.3%) | 33 (70.2%) | ||
| > 21U/ml | 4 (22.2%) | 0 | 4 (16.7.0%) | 9 (19.1%) | ||
| Unknown | 3 (17.7%) | 0 | 5 (10.6%) | |||